Premium
A review of evidence from short‐term studies leading to the prediction that diazoaminobenzene (1,3‐diphenyltriazine) is a carcinogen
Author(s) -
Bordelon Nancy R.,
Chhabra Rajendra,
Bucher John R.
Publication year - 2005
Publication title -
journal of applied toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.784
H-Index - 87
eISSN - 1099-1263
pISSN - 0260-437X
DOI - 10.1002/jat.1087
Subject(s) - carcinogen , toxicology , bioassay , micronucleus test , chemical compound , toxicity , pharmacology , chemistry , biology , medicine , genetics , biochemistry
The National Toxicology Program (NTP) is responsible for providing comprehensive toxicology evaluations of substances, while at the same time incorporating approaches to reduce, refine or replace laboratory animals in routine toxicity/carcinogenicity studies. Consistent with this, a series of metabolism studies in rodents and human liver slices, electron spin resonance spectroscopy (ESR) studies, short‐term dermal toxicity studies in rodents, and acute bone marrow micronucleus studies in mice were performed on diazoaminobenzene (DAAB, also known as 1,3‐diphenyltriazine). These studies demonstrated that DAAB is metabolized and shares similar genotoxic and toxicological properties to the known human carcinogen, benzene, and the known rodent carcinogen, aniline. These data were used to evaluate the potential carcinogenicity of DAAB without doing a 2‐year rodent bioassay. Based on this analysis, DAAB was predicted to be carcinogenic if evaluated in a 2‐year rodent bioassay. These data were evaluated to support listing DAAB in the NTP Report on Carcinogens as a substance ‘reasonably anticipated to be a human carcinogen’. The purpose of this article is to review the data developed for predicting the carcinogenicity of DAAB. Published in 2005 by John Wiley & Sons, Ltd.